Last reviewed · How we verify
Venetoclax plus HMA
Venetoclax plus HMA is a Small molecule drug developed by Gruppo Italiano Malattie EMatologiche dell'Adulto. It is currently in Phase 2 development.
At a glance
| Generic name | Venetoclax plus HMA |
|---|---|
| Sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) (PHASE2)
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) (PHASE1, PHASE2)
- Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) (PHASE1, PHASE2)
- A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies (PHASE1)
- Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker (PHASE2)
- Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent (PHASE2)
- Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD (PHASE2)
- A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Venetoclax plus HMA CI brief — competitive landscape report
- Venetoclax plus HMA updates RSS · CI watch RSS
- Gruppo Italiano Malattie EMatologiche dell'Adulto portfolio CI
Frequently asked questions about Venetoclax plus HMA
What is Venetoclax plus HMA?
Venetoclax plus HMA is a Small molecule drug developed by Gruppo Italiano Malattie EMatologiche dell'Adulto.
Who makes Venetoclax plus HMA?
Venetoclax plus HMA is developed by Gruppo Italiano Malattie EMatologiche dell'Adulto (see full Gruppo Italiano Malattie EMatologiche dell'Adulto pipeline at /company/gruppo-italiano-malattie-ematologiche-dell-adulto).
What development phase is Venetoclax plus HMA in?
Venetoclax plus HMA is in Phase 2.